Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009313 | Panoply™ Human MCM2 Knockdown Stable Cell Line | Inquiry |
| CSC-DC009319 | Panoply™ Human MCM7 Knockdown Stable Cell Line | Inquiry |
| CSC-SC009313 | Panoply™ Human MCM2 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC009319 | Panoply™ Human MCM7 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09757Z | Human MCM2 adenoviral particles | Inquiry |
| AD09763Z | Human MCM7 adenoviral particles | Inquiry |
| LV17957L | human MCM2 (NM_004526) lentivirus particles | Inquiry |
| LV17963L | human MCM7 (NM_182776) lentivirus particles | Inquiry |
| LV17964L | human MCM7 (NM_005916) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH181469 | shRNA set against Human MCM7(NM_005916.3) | Inquiry |
| SHH181487 | shRNA set against Human MCM7(NM_182776.1) | Inquiry |
| SHH181505 | shRNA set against Mouse Mcm7(NM_008568.2) | Inquiry |
| SHH181517 | shRNA set against Rat Mcm7(NM_001004203.3) | Inquiry |
| SHH339275 | shRNA set against Human MCM2 (NM_004526.3) | Inquiry |
| SHH339279 | shRNA set against Mouse MCM2 (NM_008564.2) | Inquiry |
| SHH339283 | shRNA set against Rat MCM2 (NM_001107873.2) | Inquiry |
| SHH339347 | shRNA set against Human MCM7 (NM_005916.3) | Inquiry |
| SHH339351 | shRNA set against Mouse MCM7 (NM_008568.2) | Inquiry |
| SHH339355 | shRNA set against Rat MCM7 (NM_001004203.3) | Inquiry |
| SHW000233 | shRNA set against Chicken MCM2 (NM_001006139) | Inquiry |
| SHW015416 | shRNA set against Danio rerio MCM2 (NM_173257) | Inquiry |
| SHW017735 | shRNA set against Danio rerio MCM7 (NM_212569) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB156203 | Rat MCM7 ORF clone (DQ278200.1) | Inquiry |
| MiUTR1M-07000 | MCM7 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-06166 | MCM7 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-06165 | MCM7 miRNA 3'UTR clone | Inquiry |
| CDFR007521 | Rat Mcm2 cDNA Clone(NM_001107873.2) | Inquiry |
| CDFR001351 | Rat Mcm7 cDNA Clone(NM_001004203.3) | Inquiry |
| CDFH011211 | Human MCM7 cDNA Clone(NM_005916.3) | Inquiry |
| CDFG012217 | Human MCM7 cDNA Clone(NM_182776.1) | Inquiry |
| CDCS411830 | Human MCM2 ORF Clone (BC007938) | Inquiry |
| MiUTR1R-03733 | MCM7 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00391 | MCM2 miRNA 3'UTR clone | Inquiry |
| CDCR291603 | Human MCM7 ORF Clone(NM_005916.3) | Inquiry |
| CDCB196074 | Rabbit LOC103351040 ORF clone (XM_008268639.1) | Inquiry |
| CDCR368402 | Rat Mcm7 ORF Clone(NM_001004203.3) | Inquiry |
| CDCR374544 | Rat Mcm2 ORF Clone(NM_001107873.2) | Inquiry |
| CDCS411829 | Human MCM2 ORF Clone (BC017258) | Inquiry |
| CDCR245745 | Mouse Mcm2 ORF Clone(NM_008564.2) | Inquiry |
| CDCS412482 | Human MCM7 ORF Clone (BC009398) | Inquiry |
| CDCS412483 | Human MCM7 ORF Clone (BC013375) | Inquiry |
| CDCL131365 | Human Mcm7 ORF clone (NM_008568.2) | Inquiry |
| CDCB194872 | Rabbit MCM2 ORF clone (XM_008260315.1) | Inquiry |
| CDCB191414 | Rabbit MCM7 ORF clone (XM_008248898.1) | Inquiry |
| CDCB179210 | Danio rerio MCM7 ORF Clone (NM_212569) | Inquiry |
| CDCB176891 | Danio rerio MCM2 ORF Clone (NM_173257) | Inquiry |
| CDCB161708 | Chicken MCM2 ORF Clone (NM_001006139) | Inquiry |
| CDCR324790 | Human MCM7 ORF Clone(NM_182776.1) | Inquiry |
| CDCS411828 | Human MCM2 ORF Clone (BC007670) | Inquiry |
MCM2 is a member of the minichromosome maintenance protein family. MCM2 was previously named CCNL1, BM28, and CDCL1. It plays an important role in DNA replication initiation and replication fork movement. It is closely related to cell proliferation and is a good indicator for studying tumor cell growth and evaluating the prognosis of some tumors. The MCMs protein is a nuclear protein family of six subunits, MCM2, MCM3, MCM4 (Cdc21), MCM5 (Cdc46), MCM6 (Mis5), and MCM7 (Cdc47), which have similar biological effects and play an equally important role in the process in beginning and extension of the DNA replication.
The Role of MCM2
MCM2 content is very low in quiescent cells. In proliferating and transformed cells, MCM2 content begins to increase in G1 phase, peaks in early G1 and early S, and binds to chromatin. In the S phase to the M phase, it is free MCM2, and it is decreased in the G2 phase and the M phase. Due to this cyclical change consistent with the cell proliferation process, it has been regarded as a marker of S phase cells, that is, expressed only in proliferating cells, and is considered to be a specific proliferation-related factor, and is considered to be the sign of precancerous. The level of MCM protein can be directly reflected by detecting MCM2. Therefore, MCM2 is a good indicator for studying tumor cell motility and evaluating the prognosis of some tumors. MCM2 has also been reported that it may play a role in acute myeloid leukemia.

Figure 1. Multiple Functions for Mcm2–7 ATPase Motifs during Replication Initiation. (Kang, et al. 2014)
MCM2 protein can better distinguish corresponding normal tissues, atypical hyperplasia tissues and tumor tissues, and can be used as an important biomarker for malignant tumors and dysplasia. It is a cell proliferation marker superior to proliferating cell nuclear antigen (PCNA) and Ki-67. Because PCNA is also expressed in repair cells, it affects the accuracy of PCNA reflecting cell proliferation activity; Ki-67 is not expressed in early G1, so it cannot fully reflect cell proliferation activity. MCM (including MCM2) is expressed only in cells in the proliferative cycle and can accurately and comprehensively reflect cell proliferation activity. The absence of MCM protein means that the cell has withdrawn from the proliferative cycle, becomes a differentiated mature cell or enters the G0 phase, and thus can be used as a valid indicator for determining the prognosis of the tumor.
MCM2 Protein and Cancer
Immunohistochemistry was used to detect the expression of protein MCM2 and Ki-67 in 221 cases of non-small-celllungcancer (NSCLC) tumor samples, and the regression analysis was performed on the experimental results, pathological features, clinical manifestations and survival. The study found that the stage and location of the tumor and the MCM2 staining level were significantly correlated with survival, and the MCM2 positive staining rate. MCM2 is not only highly expressed in breast cancer tissues, but also significantly associated with prognosis. The study found that MCM2 was positively correlated between normal breast (P = 0.0003) and breast cancer (P < 0.0001).
The expression of MCM2 and Ki-67 in surgically resected tumor specimens of 93 patients with esophageal squamous cell carcinoma was detected by immunohistochemistry. It was found that MCM2 was mainly expressed in the nucleus, and its expression index (LI) in esophageal squamous cell carcinoma was significantly higher than that of normal squamous epithelium (P<0.0001). MCM2 may be more reliable and effective than Ki67 in evaluating the prognosis, tumor infiltration, and tumor cell growth in patients with esophageal squamous cell carcinoma.
References: